162 related articles for article (PubMed ID: 27528077)
1. Allosteric mechanism of cyclopropylindolobenzazepine inhibitors for HCV NS5B RdRp via dynamic correlation network analysis.
Rahman MU; Liu H; Wadood A; Chen HF
Mol Biosyst; 2016 Oct; 12(11):3280-3293. PubMed ID: 27528077
[TBL] [Abstract][Full Text] [Related]
2. Probing the "fingers" domain binding pocket of Hepatitis C virus NS5B RdRp and D559G resistance mutation via molecular docking, molecular dynamics simulation and binding free energy calculations.
Manjula S; Sivanandam M; Kumaradhas P
J Biomol Struct Dyn; 2019 Jun; 37(9):2440-2456. PubMed ID: 30047829
[TBL] [Abstract][Full Text] [Related]
3. Molecular modeling and residue interaction network studies on the mechanism of binding and resistance of the HCV NS5B polymerase mutants to VX-222 and ANA598.
Xue W; Jiao P; Liu H; Yao X
Antiviral Res; 2014 Apr; 104():40-51. PubMed ID: 24462692
[TBL] [Abstract][Full Text] [Related]
4. NMR reveals the intrinsically disordered domain 2 of NS5A protein as an allosteric regulator of the hepatitis C virus RNA polymerase NS5B.
Bessa LM; Launay H; Dujardin M; Cantrelle FX; Lippens G; Landrieu I; Schneider R; Hanoulle X
J Biol Chem; 2017 Nov; 292(44):18024-18043. PubMed ID: 28912275
[TBL] [Abstract][Full Text] [Related]
5. Discovery of novel Hepatitis C virus inhibitor targeting multiple allosteric sites of NS5B polymerase.
Khalid H; Landry KB; Ijaz B; Ashfaq UA; Ahmed M; Kanwal A; Froeyen M; Mirza MU
Infect Genet Evol; 2020 Oct; 84():104371. PubMed ID: 32485331
[TBL] [Abstract][Full Text] [Related]
6. Identification of potential anti-hepatitis C virus agents targeting non structural protein 5B using computational techniques.
Polamreddy P; Vishwakarma V; Saxena P
J Cell Biochem; 2018 Nov; 119(10):8574-8587. PubMed ID: 30058078
[TBL] [Abstract][Full Text] [Related]
7. Multiple e-pharmacophore modeling, 3D-QSAR, and high-throughput virtual screening of hepatitis C virus NS5B polymerase inhibitors.
Therese PJ; Manvar D; Kondepudi S; Battu MB; Sriram D; Basu A; Yogeeswari P; Kaushik-Basu N
J Chem Inf Model; 2014 Feb; 54(2):539-52. PubMed ID: 24460140
[TBL] [Abstract][Full Text] [Related]
8. Multiple virtual screening approaches for finding new hepatitis C virus RNA-dependent RNA polymerase inhibitors: structure-based screens and molecular dynamics for the pursue of new poly pharmacological inhibitors.
Elhefnawi M; ElGamacy M; Fares M
BMC Bioinformatics; 2012; 13 Suppl 17(Suppl 17):S5. PubMed ID: 23282180
[TBL] [Abstract][Full Text] [Related]
9. Screening of hepatitis C NS5B polymerase inhibitors containing benzothiadiazine core: a steered molecular dynamics.
Nutho B; Meeprasert A; Chulapa M; Kungwan N; Rungrotmongkol T
J Biomol Struct Dyn; 2017 Jun; 35(8):1743-1757. PubMed ID: 27236925
[TBL] [Abstract][Full Text] [Related]
10. Synthesis of potent and broad genotypically active NS5B HCV non-nucleoside inhibitors binding to the thumb domain allosteric site 2 of the viral polymerase.
Pierra Rouvière C; Amador A; Badaroux E; Convard T; Da Costa D; Dukhan D; Griffe L; Griffon JF; LaColla M; Leroy F; Liuzzi M; Loi AG; McCarville J; Mascia V; Milhau J; Onidi L; Paparin JL; Rahali R; Sais E; Seifer M; Surleraux D; Standring D; Dousson C
Bioorg Med Chem Lett; 2016 Sep; 26(18):4536-4541. PubMed ID: 27520942
[TBL] [Abstract][Full Text] [Related]
11. Discovery of HCV NS5B thumb site I inhibitors: core-refining from benzimidazole to indole scaffold.
Zhao F; Liu N; Zhan P; Jiang X; Liu X
Eur J Med Chem; 2015 Apr; 94():218-28. PubMed ID: 25768704
[TBL] [Abstract][Full Text] [Related]
12. Combined 3D-QSAR, molecular docking, molecular dynamics simulation, and binding free energy calculation studies on the 5-hydroxy-2H-pyridazin-3-one derivatives as HCV NS5B polymerase inhibitors.
Yu H; Fang Y; Lu X; Liu Y; Zhang H
Chem Biol Drug Des; 2014 Jan; 83(1):89-105. PubMed ID: 23941500
[TBL] [Abstract][Full Text] [Related]
13. Thumb inhibitor binding eliminates functionally important dynamics in the hepatitis C virus RNA polymerase.
Davis BC; Thorpe IF
Proteins; 2013 Jan; 81(1):40-52. PubMed ID: 22855387
[TBL] [Abstract][Full Text] [Related]
14. Allosteric ligands for the pharmacologically important Flavivirus target (NS5) from ZINC database based on pharmacophoric points, free energy calculations and dynamics correlation.
Khan A; Saleem S; Idrees M; Ali SS; Junaid M; Chandra Kaushik A; Wei DQ
J Mol Graph Model; 2018 Jun; 82():37-47. PubMed ID: 29677482
[TBL] [Abstract][Full Text] [Related]
15. Combination of pharmacophore hypothesis and molecular docking to identify novel inhibitors of HCV NS5B polymerase.
Harikishore A; Li E; Lee JJ; Cho NJ; Yoon HS
Mol Divers; 2015 Aug; 19(3):529-39. PubMed ID: 25862642
[TBL] [Abstract][Full Text] [Related]
16. Repositioning of RdRp Inhibitors Against HCV NS5B Polymerase Utilizing Structure-Based Molecular Docking.
Tarannum H; Nandi S
Comb Chem High Throughput Screen; 2022; 25(4):702-719. PubMed ID: 33475069
[TBL] [Abstract][Full Text] [Related]
17. Structural and regulatory elements of HCV NS5B polymerase--β-loop and C-terminal tail--are required for activity of allosteric thumb site II inhibitors.
Boyce SE; Tirunagari N; Niedziela-Majka A; Perry J; Wong M; Kan E; Lagpacan L; Barauskas O; Hung M; Fenaux M; Appleby T; Watkins WJ; Schmitz U; Sakowicz R
PLoS One; 2014; 9(1):e84808. PubMed ID: 24416288
[TBL] [Abstract][Full Text] [Related]
18. Understanding the drug resistance mechanism of hepatitis C virus NS5B to PF-00868554 due to mutations of the 423 site: a computational study.
Jiao P; Xue W; Shen Y; Jin N; Liu H
Mol Biosyst; 2014 Apr; 10(4):767-77. PubMed ID: 24452008
[TBL] [Abstract][Full Text] [Related]
19. Combined 3D-QSAR, molecular docking and molecular dynamics study on the benzimidazole inhibitors targeting HCV NS5B polymerase.
Wang Z; Chen Z; Li J; Huang J; Zheng C; Liu JP
J Biomol Struct Dyn; 2020 Mar; 38(4):1071-1082. PubMed ID: 30915896
[TBL] [Abstract][Full Text] [Related]
20. 2-Heteroarylimino-5-arylidene-4-thiazolidinones as a new class of non-nucleoside inhibitors of HCV NS5B polymerase.
Küçükgüzel I; Satılmış G; Gurukumar KR; Basu A; Tatar E; Nichols DB; Talele TT; Kaushik-Basu N
Eur J Med Chem; 2013 Nov; 69():931-41. PubMed ID: 24161679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
